Singapore: ERT, a US-based service provider to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), has established a fully-owned subsidiary, ERT Asia Group, in Japan.

ERT has completed registration for Kabushiki Kaisha (KK) in Japan to broaden its local services in Japan. Along with this registration, ERT will grow the number of local resources in Japan that will work directly with its customers to deploy Japan-based projects.

Having already deployed solutions in over 1,200 studies in Asia, this expansion enhances ERT's capabilities to support the growing number of biopharmaceutical companies who are utilizing its eClinical solutions in trials throughout Asia. ERT is the industry leader in delivering important health outcomes research services in support of clinical trials that include the enrollment of subjects in Asia.

"We are pleased to have collaborated with so many global and domestic biopharmaceutical organizations on their Japanese-based clinical trials and to have delivered the valuable data they need to evaluate their products' safety and efficacy profiles," said Mr Robert Brown, VP, business development Asia Pacific, ERT.

He further added, "Increasing the number of local ERT resources will enable us to work more collaboratively with our customers and our excellent partners in Japan and other Asian countries to increase efficiencies in study execution and improve the integrity of data collected in clinical research."